“…T o the Editor, Sze et al used the U.S. Food and Drug Administration Adverse Event Reporting System database to examine adverse events with medications used to treat overactive bladder (OAB). 1 Pharmacovigilance using postmarketing data is an important tool for identifying adverse events not captured by initial clinical trials. Such data are not without limitations, and reports are susceptible to bias.…”